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the polymeric immunoglobulin receptor (pigR) transports immunoglobulins from the basolateral to 
the apical surface of epithelial cells. PIgR was recently shown to be associated with kidney dysfunction. 
the immune defense is initiated at the apical surface of epithelial cells where the n-terminal domain 
of pIgR, termed secretory component (SC), is proteolytically cleaved and released either unbound 
(free SC) or bound to immunoglobulins. The aim of our study was to evaluate the association of pIgR 
peptides with the cardio-renal syndrome in a large cohort and to obtain information on how the Sc is 
released. We investigated urinary peptides of 2964 individuals available in the Human Urine Proteome 
Database generated using capillary electrophoresis coupled to mass spectrometry. The mean amplitude 
of 23 different pIgR peptides correlated negatively with the estimated glomerular filtration rate (eGFR, 
rho = −0.309, p < 0.0001). Furthermore, pIgR peptides were significantly increased in cardiovascular 
disease (coronary artery disease and heart failure) after adjustment for eGFR. We further predicted 
potential proteases involved in urinary peptide generation using the Proteasix algorithm. Peptide 
cleavage site analysis suggested that several, and not one, proteases are involved in the generation 
of the SC. In this large cohort, we could demonstrate that pIgR is associated with the cardio-renal 
syndrome and provided a more detailed insight on how pIgR can be potentially cleaved to release the 
SC.
The polymeric immunoglobulin receptor (pIgR) is a transmembrane protein that is expressed in many mucosal 
epithelial cell types. PIgR at the basolateral plasma membrane can bind to immunoglobulins of the IgA and IgM 
isotype. As its main immune defense function, the pIgR transports polymeric immunoglobulins (pIgs) across epi-
thelia to mucosal secretions at the apical compartment where pIgs are cleaved off from pIgR, leaving a fragment of 
pIgR called secretory component (SC) covalently attached to the secreted pIgs. Therefore, SC is directly involved 
in the protective function of secretory IgA. In addition, free SC exhibits scavenger properties with respect to 
enteric pathogens1.
In general, the glycosylated pIgR is a single pass type I receptor and consists of an extracellular and a trans-
membrane region and a cytoplasmic tail2. The extracellular immunoglobulin-binding region is further divided 
into five domains of around 100 amino acids which are highly conserved3. A sixth more distantly related domain 
follows these five and includes the transmembrane region of the molecule2. This sixth domain is involved in the 
enzymatic cleavage and release of the pIgR into the intestinal lumen as SC. However, the mechanism by which 
the pIgR is cleaved into the SC remains elusive4. The prediction of a consensus cleavage site is hampered, because 
the sequence and the length of the linker peptide is poorly conserved across species and the C-terminus of the SC 
has not been identified5. Therefore, the identity of the protease that cleaves pIgR to SC remains unknown to date.
Cytoplasmic and membranous expression of the pIgR was observed mostly in the gall- and urinary bladder, 
kidney, and gastrointestinal mucosa6. However, in contrast to studies of organs like the intestine, the regulation 
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of pIgR in human kidneys was, until previously, incompletely investigated. In a recent study, Krawczyk et al. 
investigated the localization and regulation of pIgR in human kidneys7. They were able to show that human pIgR 
is expressed in proximal tubules and glomeruli. Furthermore, they demonstrated that during chronic kidney 
disease (CKD) the expression of pIgR in the tubules becomes prevalent, associated with increased levels of uri-
nary secretory immunoglobulins. Their results indicated that elevated pIgR expression is a substantial part of the 
tubular response to injury, providing an explanation for the increased levels of secreted pIgs found in urine from 
injured kidneys.
Due to the fact that heart and kidneys are involved in maintaining hemodynamic stability and organ perfusion 
through an intricate network, the pIgR might also be associated to coronary artery diseases (CAD). However, the 
only link between pIgR and atherosclerosis is the elevated level of this protein in extracellular vesicles from indi-
viduals with acute coronary syndrome, although inclusion of this parameter did not improve disease detection 
over conventional risk factors or troponin I8. Elevated levels of total serum IgA have been reported in patients 
with severe atherosclerosis or with previous myocardial infarction or other major ischemic events9,10.
Therefore, the aim of this study was to investigate whether altered pIgR expression is associated with 
cardio-renal syndrome using urinary proteome analysis. In addition, the analysis of endogenous urinary peptides 
could provide further information about the potential cleavage of pIgR to release the SC.
Results
Release of pIgR peptides in urine. We investigated urinary pIgR peptides which were identified previ-
ously and stored in the Human Urinary Proteome database11. In total, 23 different pIgR-derived naturally occur-
ring peptides were found in urine by proteome analysis. These peptides showed a high degree of sequence overlap, 
covering mainly domain 6 of the extracellular region (Fig. 1, green) and the first amino acids (AA) from the 
transmembrane region (Fig. 1, orange) in the pIgR protein (from AA 576 to 648). Most of the peptides showed 
an inconspicuous cleavage site at their C-terminus and some also at their N-terminus. However, there were 6 
pIgR-peptides with their N-terminus at AA position 605 and 2 peptides with a C-terminus at AA position 604, 
which are indicative for a specific proteolytic cleavage site. However, there seem to be further cleavage sites before 
AA positions 610 and 576.
In order to predict the proteases possibly involved in the generation of the urinary pIgR-peptides, in-silico 
protease prediction was performed with the open-source tool Proteasix12. By using this bioinformatics approach 
on the naturally occurring peptides as cleaved end products it is possible to track back to the enzymes potentially 
responsible for the generation of these peptides. The majority of human proteases have several protein targets and 
therefore one peptide sequence might be cleaved by different proteases. The analysis yielded a list of 52 endopep-
tidases putatively responsible for the generation of the identified pIgR-peptides in urine (Supplementary Table 1). 
From the 52 predicted proteases, 12 proteases were most frequently selected (predicted protease in ≥ 50% of 
total cleavage assignments) in the Proteasix analysis including calpains CAPN1 and CAPN2, cathepsins CTSB, 
CTSD and CTSG, matrix metalloproteinases MMP14, MMP25, MMP3, MMP7 and MMP9, as well as pepsin A-3 
(PEPA3) and meprin A subunit alpha (MEP1A). Furthermore, when focussing on the three potential cleavage 
Figure 1. Identified endogenous urinary pIgR peptides and their position in the pIgR protein sequence. D1-
D6: Domain 1–6; TM: transmembrane region. The table shows the frequency of each individual peptide in the 
analysed samples, the correlation factor rho with estimated glomerular filtration rate (eGFR) and the associated 
p-value. Arrows indicate the individual peptides with the highest negative correlations with eGFR.
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Figure 2. (A) Scatter diagram of the correlation between mean amplitudes of the pIgR peptides (LOG) and 
estimated glomerular filtration rate (eGFR). (B) Mean pIgR peptide amplitudes (±95% CI) in urine distributed 
to the different CKD stages. *Indicates p < 0.05 in comparison to all different CKD stages.
Figure 3. (A) Mean pIgR peptide amplitudes (±95% CI) and (B) estimated glomerular filtration rate (eGFR) 
(±SD) in urine of patients with different kidney disease conditions and healthy controls. *Indicates p < 0.05 
in comparison to healthy controls. ADPKD: autosomal dominant polycystic kidney disease, MCD: minimal 
change disease, MGN: membranous glomerulonephritis, IgAN: IgA nephropathy, FSGS: focal segmental 
glomerulosclerosis, DKD: diabetic kidney disease.
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sites of the pIgR-protein for the release of the SC (mentioned above) CAPN1, CAPN2, CTSD, CTSG, MMP3, 
MMP7, MMP9, PEPA3, and MEP1A were most frequently predicted.
Association of urinary pIgR peptides with estimated glomerular filtration rate (eGFR). To 
investigate the association of these pIgR-peptides with kidney function, we used 2449 relevant (investigated in 
the context of CKD) proteome datasets with patient information on their eGFR. Based on the assumption that 
these peptides depict the whole spectrum of pIgR protein abundance, we calculated the mean amplitude of all 
peptides in each CKD aetiology and healthy control datasets. When investigating association of mean pIgR abun-
dance with eGFR of the total cohort, a significant negative correlation was detected (rho = −0.309, p < 0.0001) 
as shown in Fig. 2A. The correlation analysis without the controls (n = 1243; rho = −0.376) is even significantly 
better (p = 0.029) compared to the correlation with the controls. Assessment of the correlation of the individual 
peptides in all individuals showed that 10 out of the 23 peptides contributed to this correlation (table in Fig. 1). 
However, these individual significant correlations were very variable ranging from rho = −0.075 to -0.412. Some 
of the peptides displayed a stronger negative correlation than the correlation of the combined peptides includ-
ing peptide AA 598–606 (rho = −0.412), AA 604–639 (rho = −0.361), and AA 614–640 (rho = −0.348) (black 
arrows in Fig. 1). We also investigated the correlation of the pIgR peptides with urinary albumin concentrations 
which was positive (rho = 0.210; p < 0.0001). Finally, we looked at the pIgR amplitudes divided into the different 
CKD stages. As depicted in Fig. 2B, the combined pIgR peptide amplitudes were significantly increased with 
higher CKD stages.
After the investigation of the association of the pIgR-peptides with the eGFR in the full cohort, we also investi-
gated their mean amplitude in different kidney disease etiologies. We investigated the following CKDs: autosomal 
dominant polycystic kidney disease (ADPKD), minimal change disease (MCD), membranous glomerulonephri-
tis (MGN), IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), ANCA-associated vasculitis, 
nephritis, nephrosclerosis, diabetic kidney disease (DKD), and other CKDs (e.g. solitary kidneys, other glomeru-
lar diseases, urologic/reflux nephropathy, cystic kidneys). As demonstrated in Fig. 3A, the lowest mean amplitude 
of pIgR is observed in urine of patients with MCD and the highest levels are in the urine of patients suffering from 
DKD. However, the differences between the mean amplitude of pIgR-peptides in healthy controls and CKDs 
differs significantly only with the disease groups IgAN, FSGS, vasculitis, nephritis, nephrosclerosis, DKD, and 
all other CKDs. In addition, as observed above, although with some exceptions, inverse association between the 
pIgR-peptide mean amplitude and eGFR is evident (Fig. 3B).
In addition, we performed further analyses with Proteasix by using only the pIgR peptides which were sig-
nificantly associated with eGFR in each CKD aetiology and predicted the proteases preferentially involved in 
cleavage of those peptides (Supplementary Table 2). The following potential proteases for the different CKD aeti-
ologies were identified: ADPKD (MMP7), MCD (CTSB, CTSD, CTSE, MEP1A, MMP7, PGA3), MGN (MMP3, 
MMP7, MMP9, MMP13, MMP14), IgAN (MMP7), FSGS (MMP3, MMP7), vasculitis (PGA3), nephritis (MMP7, 
MMP9), nephrosclerosis (MMP7), and DKD (MMP9).
Regulation of urinary pIgR peptides in cardiovascular diseases. To investigate the association of 
pIgR peptides with cardiovascular diseases, we extracted additional urinary proteome data from the Human 
Urinary Database with respect to heart failure and CAD with patient information on the eGFR. We compared 
the urinary levels of pIgR peptides in these CAD with those of the healthy controls. To eliminate the influence 
of eGFR on the pIgR levels, we adjusted the proteome data for this parameter with the use of multiple regression 
analysis. As shown in Fig. 4A, the levels of pIgR peptides in patients with heart failure and CAD when com-
pared with healthy controls are significantly increased. Furthermore, we investigated the urinary albumin excre-
tion, which can also be a risk factor for cardiovascular disease. We used a data subset of CVD patients with an 
Figure 4. (A) Adjusted (for eGFR) mean pIgR peptide amplitudes (±95% CI) in urine of patients with different 
cardiovascular disease conditions (CAD and heart failure) and healthy controls. (B) Scatter diagram of the 
correlation between mean amplitudes of the pIgR peptides (LOG) and urinary albumin excretion (LOG) in 
patients with cardiovascular disease conditions and with an eGFR > 60 ml/min/1.73m2. *Indicates p < 0.05 in 
comparison to healthy controls. CAD: coronary artery disease.
5Scientific RepoRtS |         (2020) 10:8291  | https://doi.org/10.1038/s41598-020-65154-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
eGFR > 60 ml/min/1.73m2 (n = 101). There was a significant positive correlation of albumin with pIgR peptides 
levels (rho = 0.277; p = 0.005) in the heart failure and CAD patients without CKD (see Fig. 4B).
Discussion
Based on a large dataset representing approximately 3000 patients, our data support the results by Krawczyk et 
al. that urinary SC levels of the pIgR protein are positively correlated to the severity of kidney injury in patients 
with kidney disease7. We could further confirm the findings reported by Krawczyk et al. that the pIgR amplitude 
is lower (but not significantly) in the urine of MCD patients than it is in healthy controls. Finally, some pIgR pep-
tides are also included in the peptide-based classifier CKD273 which was proven in several studies to have a high 
accuracy in the early diagnosis and the prediction of CKD progression13,14. Therefore, the current study confirms 
the association of pIgR peptides with renal (dys)function. Furthermore, we were able to demonstrate that there 
is also an association of pIgR with CAD and heart failure. Due to the fact that pIgR/SC is not expressed in heart 
cells15, our findings point towards inflammatory pathways with respect to cardiovascular disease risk. A first hint 
in this direction was shown in a study where pIgR is associated with coronary atherosclerosis in coronary vessels 
of individuals chronically exposed to increased ambient concentrations of traffic air pollution16. In general, we 
showed with this study that the large collection of clinical and proteomics data available the Human Urinary 
Proteome Database can be of great use for the evaluation of specific urinary peptide levels under different disease 
conditions.
In addition, the identification of naturally occurring urinary pIgR peptides may also provide further insights 
into the structure of the SC of the pIgR protein. First, the vast majority of the identified endogenous peptides are 
derived from domain 6 of the extracellular region in the pIgR protein (see Fig. 1), as described in the study of 
Sunagawa et al.17. Interestingly, the lowest AA number of the identified urinary peptides starts at position 576 of 
the pIgR protein and not at position 575. Furthermore, the identified urinary pIgR peptides with the highest AA 
number end at position 643 which means that the SC also includes parts of the suggested transmembrane region3. 
This confirms the observation that based on cloning and sequencing of DNA complementary to pIgR mRNA 
isolated from rabbit liver, the sixth domain also included a portion of the membrane-spanning domain2.
Several groups tried to determine the exact cleavage site for the secretion of SC5,18,19. In a study using a recom-
binant vaccinia virus-mediated transient expression system, the importance of domain 6 of the pIgR for cleavage 
of the receptor was demonstrated19. A highly conserved 9-amino acid sequence is present in this region in various 
species17. This 9-amino acid sequence FAEEKAVAD ranging from position 605 to position 613 in pIgR is pre-
dicted to encode an α-helical region that is critical for pIgR cleavage17. In our study, we found that 10 of the 24 
different urinary peptides include these 9 AAs. Furthermore, based on the peptide sequences it seems that there 
are at least 3 cleavage sites specific for calpains, cathepsins, matrix metalloproteinases, pepsin A-3, and meprin A 
subunit alpha. These results confirm the hypothesis from Kaetzel et al. that more than just one potential protease 
enables the release of the SC4. Regulation via differential protease activity seems necessary to maintain tissue 
homeostasis and directly linked to the generation of pIgR peptides associated with CKD20,21. Bioinformatics pep-
tide centric tools have been developed in order to determine which proteases are potentially responsible for the 
changes in the urinary peptidome during CKD12,22. In the present study, we were able to specify several potential 
proteases for the generation of the identified urinary pIgR-peptides which belong to the family of metallopro-
teinases, cathepsins, calpains, mephrins, and pepsins. Out of these, four were already described to be deregulated 
in CKD patients: MMP3, MMP7, MMP9, and CTSD20. The CKD aetiology-based protease prediction suggested 
some relatively specific proteases for the different CDK aetiologies which remains to be confirmed. The dysreg-
ulation of matrix metalloproteinases has been linked to renal fibrosis progression23, as well as to CAD24. CTSD, 
Diagnosis
cohort sex age (years)
eGFR (ml/
min/1.73 m2) u-albumin (mg/L) [LOG]
pIgR-peptide amplitude 
[LOG]





Healthy control 1206 53 48 17 88 14 1.29 1.22–1.37 287.20 274.31–300.70
ADPKD 299 46 33 9 84 22 28.07 19.16–41.12 283.84 259.07–310.97
MCD 26 77 46 19 77 28 572.93 90.15–3640.95 240.93 139.33–416.64
MGN 50 72 53 14 75 32 666.95 346.39–1284.19 266.03 190.53–371.45
IgAN 114 67 45 15 61 35 283.85 185.96–433.28 368.64 304.07–446.93
FSGS 47 60 47 19 43 24 376.15 166.41–850.26 375.95 247.80–570.39
Vasculitis 43 51 65 9 46 21 203.83 135.34–306.97 373.15 254.51–547.09
Nephritis 115 36 49 18 60 30 122.77 75.36–200.00 430.80 352.44–526.57
Nephrosclerosis 133 66 67 14 38 21 43.39 28.60–65.82 522.50 450.12–606.52
DKD 304 65 64 12 47 24 187.59 153.74–228.91 538.50 479.60–604.64
other CKDs 112 58 60 17 45 18 29.66 21.90–40.17 448.04 378.88–529.82
CAD 263 67 64 11 56 27 18.87 13.80–25.80 434.26 384.79–490.09
Heart failure 252 61 67 12 65 25 26.76 13.71–52.24 378.06 340.23–420.10
Table 1. Patients data in the different disease conditions. ADPKD: autosomal dominant polycystic kidney 
disease, MCD: minimal change disease, MGN: membranous glomerulonephritis, IgAN: IgA nephropathy, 
FSGS: focal segmental glomerulosclerosis, DKD: diabetic kidney disease, CKD: chronic kidney disease, CAD: 
coronary artery disease.
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also verified in a previous study, is known to mediate inflammation25 and was reported to be in increased levels 
in human kidney tissue of patients with CKD, especially in the areas of tubular damage26. Thus, the findings of 
protease dysregulation support an imbalance of inflammatory and fibrotic processes in CKD22. However, the 
predicted protease activity has to be confirmed by lab-based generated evidence.
In conclusion, based on data focussing on urinary peptides in a large cohort of almost 3000 individuals, this 
study supports recent findings that pIgR is correlated with changes in kidney function and with an association 
to coronary artery disease. Furthermore, this study provides some first hints into the mechanisms how pIgR can 
potentially be cleaved to release the SC.
Materials and Methods
For this study urinary proteome data stored in the Human Urine Proteome Database11 obtained by capillary elec-
trophoresis coupled to mass spectrometry was used. This database available at Mosaiques Diagnostics (Hannover, 
Germany) includes anonymized clinical information of participants enrolled in several studies as well as urinary 
proteomic data. The study was approved by the ethics committee from Hannover Medical School, Germany (ID 
3116–2016), fulfilling all the requirements on the protection of the individuals participating in medical research 
and in accordance with the principles of the Declaration of Helsinki27. All data sets received were anonymized. 
Urine samples were collected from 20 different centres: Steno Diabetes Center (Gentofte, Denmark; n = 67); 
Austin Health and Northern Health, University of Melbourne, (Melbourne, Australia; n = 20); Hannover Medical 
School (Hannover, Germany; n = 380); Charité (Berlin, Germany; n = 105); RWTH Hospital Aachen (Aachen, 
Germany; n = 54); LMU Munich (Munich, Germany; n = 70); Technical University of Munich (Munich, 
Germany; n = 8); Human Nutrition and Metabolism Research and Training Center, Karl Franzens University 
of Graz (Graz, Austria; n = 37); Barbara Davis Center for Childhood Diabetes, University of Colorado Denver 
(Denver, USA; n = 31); University of Virginia (Charlottesville, Virginia, USA; n = 10); University of Alabama 
(Birmingham, Alabama, USA; n = 17); Charles University (Prague, Czech Republic; n = 28); University of Skopje 
(Skopje, Macedonia; n = 127); University Medical Center (Groningen, The Netherlands; n = 46); INSERM 
(Toulouse, France; n = 65); RD-Néphrologie, Néphrologie Dialyse St. Guilhem (Montpellier, France; n = 42); 
University of Leuven (Leuven, Belgium; n = 488); Ghent University (Ghent, Belgium; n = 393); University 
Hospital Zürich (Zürich, Switzerland; n = 268); and BHF Glasgow Cardiovascular Research Centre (Glasgow, 
UK; n = 451). Sample collection was performed in accordance to local ethics requirements and all individuals 
gave written informed consent. The total number of datasets used for this study was n = 2707.
The estimated glomerular filtration rate (eGFR) was calculated from serum creatinine using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation28. Table 1 summarizes patient numbers, eGFR 
values, and pIgR peptide amplitudes in the different disease conditions.
protease prediction
The open-source tool for protease prediction – Proteasix (www.proteasix.org) was used for the analysis to link 
naturally occurring peptides in urine to the proteases potentially involved in their generation12. Proteasix uses 
information about naturally occurring peptides i.e. corresponding protein UniProt ID and start/stop amino acid 
position to predict potential cleaving proteases. Proteasix retrieves information about cleavage sites from protease 
databases (MEROPS, BRENDA) considering also cleavage site restrictions (from ENZYME database). A list of 
predicted proteases is generated as a result of the analysis.
Statistical methods. For statistical analysis MedCalc software version 12.7.5.0 (SAS Institute, INC., Cary; 
NC, USA) was used. Because the amplitudes of the peptides across the samples are not normally distributed, we 
used the nonparametric Spearman’s rank correlation coefficient (rho) for estimating the correlation of pIgR pep-
tides with eGFR or urinary albumin. Means were compared using one-way ANOVA followed by Tukey-Kramer 
test for multiple comparisons. The pIgR levels were adjusted for eGFR with multiple regression analysis. A p-value 
of 0.05 was selected as the significance level.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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